Jean Boulle Group Receives US$47 million Cash Investment from a New Major Strategic Investor in its Proprietary VDYNE Technology – Set to Disrupt the Market for Heart Valve Replacement

Luxembourg 24 October 2022 The Jean Boulle Group (“the Group”) is pleased to announce a US$47 million cash investment (“the Investment”) in Jean Boulle Medtech’s proprietary VDYNE heart valve technology from a new major strategic investor. The proceeds of the Investment will be used to accelerate human clinical trials of VYDNE’s novel prosthetic tricuspid valve which…

VDYNE receives major award in recognition of ground- breaking heart valve replacement technology

VDYNE, INC, Inc. (“VDYNE” or “the Company”), a privately held medical device company founded by Jean Boulle Medtech to develop a transcatheter replacement valve for the treatment of tricuspid regurgitation (“TR”), announced today that it is the co-recipient of the Innovations in Cardiovascular Interventions & High-Tech Science Industry World Startup Competition 2020. This award is one of the world’s most significant and prestigious awards for medical interventions (ICI 2020).